Governance - Evotec

IR & ESG Stock Information Financials Publications News IR & ESG Events Annual General Meeting ESG ESG Performance & Reporting Environment Social Governance Declaration of Compliance with the German Corporate Governance Code Articles of Association Information on the time of service to date of the proposed auditing firm Management Board Supervisory Board Remuneration of Management and Supervisory Board Disclosure of Management Transactions Directors' Shareholdings Share Performance Plans Compliance & Code of Conduct EVOwhistle Whistleblowing Platform Contact IR & ESG

The actions of Evotec SE’s management and oversight bodies are determined by the principles of good and responsible Corporate Governance. An effective Corporate Governance is crucial for the Company’s business affairs as well as for capital market communication. This has always been of utmost significance to Evotec. With our commitment to complying with highest Corporate Governance standards we demonstrate our dedication to well-balanced and transparent rules to the market participants and internally emphasise the importance of our clearly defined management tools and responsibilities.

For further information and documents concerning the Evotec Corporate Governance regarding Environmental Social Government (ESG) please refer to the ESG section on our website.

Our definition of good Corporate Governance

Due to our shares’ listings on the Frankfurt Stock Exchange and on NASDAQ and in respect of our international stakeholder base, Evotec recognises both German and international Corporate Governance standards. Good and transparent Corporate Governance ensures that the Company is managed and controlled in a responsible manner, with the objective of sustainable creation of value. The Management Board and Supervisory Board are convinced that compliance with high standards of Corporate Governance is a key factor of success. This also includes integrity in our dealings with employees, partners, shareholders and the public, which is demonstrated by the exemplary conduct of the Company’s management and controlling bodies. As a service provider and collaboration partner, we depend on our ability to win and retain the trust of our partners and customers through impeccable behaviour. Our objective is to be credible, solid and reliable and act accordingly. Evotec's Corporate Governance is therefore regularly reviewed and enhanced by the Management Board and the Supervisory Board.

As part of the management strategy, we define and communicate specific goals on an annual basis. To accomplish these targets, we rely on the enterprise and initiative of our managers and employees. We achieve consensus on clearly defined objectives, and we regularly monitor how well we are meeting them. These agreements on targets are a key element of our leadership philosophy and an integral part of our remuneration system. To strengthen the governance of a sustainable business, a number of ESG measures are part of our Management Board’s short-term incentive plans (STI).

To further improve our sustainability governance, the Supervisory Board implemented a dedicated sub-committee for ESG topics in June 2022. This committee is composed of three Supervisory Board members, and is led by its Chairperson Constanze Ulmer-Eilfort, who has a strong background in governance. In addition, the CEO, the Global Head of HR and the Head of Global ESG at Evotec are regular participants in the committee’s meeting, which are held every two months. The Chairperson and the Head of Global IR & ESG are in regular contact between meetings.

Please find the current Declaration of Coporate Management below.

Downloads

Declaration of Corporate Management 2022PDF, 557.4 KB

Declaration of Corporate Management 2021PDF, 401.4 KB

Former Declarations of Corporate Management
(2013-2020)PDF, 2.0 MB

Declaration of Compliance by the Management Board and Supervisory Board with the German Corporate Governance Code for the year 2022

The German Corporate Governance Code in its current version as of 28 April 2022 (the ‘Code’) contains principles, recommendations and suggestions for the Management Board and the Supervisory Board that are intended to ensure that the company is managed in its best interests. The Code highlights the obligation of Management Boards and Supervisory Boards – in line with the principles of the social market economy – to take into account the interests of the shareholders, the enterprise’s workforce and the other groups related to the enterprise (stakeholders) to ensure the continued existence of the enterprise and its sustainable value creation (the enterprise’s best interests).

With the following exceptions, Evotec complies with all recommendations of the Code and the majority of the Code’s suggestions. In December 2022, Evotec’s Management Board and Supervisory Board declared in accordance with Section 161 of the German Stock Corporation Act (AktG):

“Evotec SE has complied in 2022 with the recommendations of the Governmental Commission on the German Corporate Governance Code (the “Code”) as published in the official section of the Federal Gazette and intends to comply in the future with the recommendations of the Code, with the following exception:

Notwithstanding Section C.5 of the Code, Prof. Dr. med. Löw-Friedrich, Chief Medical Officer of UCB SA and Chairperson of Evotec‘s Supervisory Board, has also a seat in the Supervisory Board of Fresenius SE & Co. KGaA. In exercising her mandate as Chairperson of the Supervisory Board of Evotec SE, Prof. Dr. med. Iris Löw-Friedrich always had devoted sufficient time to perform her function to the extent required. Prof. Dr. med. Löw-Friedrich has plausibly demonstrated that this will also be the case in the future.”

Hamburg, December 2022

Management Board Supervisory Board

Downloads

Declaration of compliance of the German Corporate Governance Code for the year 2022PDF, 55.8 KB

Previous Corporate Governance Declarations (2015-2022)PDF, 154.3 KB

German Corporate Governance Code

The German Corporate Governance Code (the “Code”) presents essential statutory regulations for the management and supervision (governance) of German listed companies and contains internationally and nationally recognised standards for good and responsible governance. The Code aims at making the German Corporate Governance system transparent and understandable. Its purpose is to promote the trust of international and national investors, customers, employees and the general public in the management and supervision of listed German stock corporations.

Downloads

German Corporate Governance Code 2017PDF, 231.4 KB

German Corporate Governance Code 2019PDF, 688.7 KB

Articles of Association

Please find below the latest Articles of Association of Evotec SE as of 5 July 2023.

Downloads

Articles of Association
(5 July 2023)PDF, 478.4 KB

Information on the time of service to date of the proposed auditing firm and the signatory auditors

Please find below the information on the time of service to date of the proposed auditing firm and the signatory auditors.

Downloads

Information on the time of service to date of the proposed auditing firm and the signatory auditorsPDF, 50.4 KB

Two-tier management and control system: Management Board and Supervisory Board

A basic feature of the corporate governance structure at Evotec SE is its two-tier system, with a clear distinction between management by the Management Board and supervision by the Supervisory Board. The Management Board is responsible for leading the Company and represents it externally. The Supervisory Board’s task is to appoint and dismiss the members of the Management Board and monitor their activities. Under German law the Supervisory Board may not take any operational management decisions. Both decision-making bodies work together closely for the good of the Company, however, and have as their joint objective long-term sustainable growth prospects for its shareholders. The General Meeting is one of the Company’s decision-making bodies and represents the interests of shareholders.

Two-tier management and control system: Management Board and Supervisory Board

Management Board

The Management Board reports to the Supervisory Board in writing and orally on an ongoing basis and provides it with detailed information about the status of the Company. This includes monthly reports by the Management Board, in which it presents the financial results for the previous month in writing, along with detailed comments and explanations. The Management Board also presents the budget for the coming financial year and the medium-term planning to the Supervisory Board. In addition, the Management Board is obliged to notify the Supervisory Board in good time of all transactions that could have a significant impact on the Company’s profitability or liquidity. This enables the Supervisory Board to make comments on such transactions before they are executed.

Above and beyond this exchange of information and the discussions between the Supervisory Board and the Management Board, the Supervisory Board Chair and the Chair of the Management Board (CEO), as well as other Management Board members, discuss current and ongoing topics whenever this is appropriate.

Dr Werner Lanthaler

Chief Executive Officer

Dr Cord Dohrmann

Chief Scientific Officer

Dr Matthias Evers

Chief Business Officer

Dr Craig Johnstone

Chief Operating Officer

Laetitia Rouxel

Chief Financial Officer

Dr Werner Lanthaler

Chief Executive Officer

Dr Cord Dohrmann

Chief Scientific Officer

Dr Matthias Evers

Chief Business Officer

Dr Craig Johnstone

Chief Operating Officer

Laetitia Rouxel

Chief Financial Officer

Dr Werner Lanthaler Chief Executive Officer

Dr Werner Lanthaler (born in 1968, Austrian citizen) was appointed Chief Executive Officer of Evotec on 06 March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in economics from Vienna University, earned his Master’s degree from Harvard University and holds a degree in Psychology. Further, Dr Werner Lanthaler serves in the Board of Directors of AC Immune SA (since July 2018).

Dr Cord Dohrmann Chief Scientific Officer

Dr Cord Dohrmann (born in 1964, German citizen) joined Evotec as Chief Scientific Officer and Member of the Management Board in 2010. Dr Dohrmann has spent over 25 years in biomedical research at leading academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tübingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr Dohrmann completed his MA thesis at the Max Planck Institute in Tübingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining a Max Planck Institute spin-off company, DeveloGen, in 1999. During his ten-year tenure, he served the company in various management positions including CEO, leading DeveloGen from a start-up to an internationally recognised metabolic disease company. Dr Cord Dohrmann is a member of the Supervisory Boards of Eternygen and Breakpoint Therapeutics, a Non-Executive Member of the Board of Directors of Facio Therapies and a Board Observer of Immunitas Inc. He has been advising the European Commission, the Max Planck Institute as well as various venture capital firms. In February 2021, Dr Dohrmann was appointed to the German Council of Science and Humanities.

Dr Matthias Evers Chief Business Officer

Matthias (born in 1973, German citizen) was appointed as Chief Business Officer of Evotec on 01 May 2022. Matthias is responsible for business development, digital technology, and strategy across the entire company. Prior to joining Evotec, Matthias accumulated 20 years of experience as Senior Partner with the consulting firm McKinsey & Company where he co-led R&D in Life Sciences globally and served on the Firm’s most senior Knowledge and People Committees, respectively. He also spearheaded venture-type, company building efforts for biotech and health tech companies in Europe. Matthias gained significant exposure to the U.S., China, India, and Europe, where he helped R&D organisations to excel at innovation through large-scale performance transformations, innovation programmes, and novel approaches for maximising value from new assets, capabilities, and technologies. His areas of expertise include convergence of biology and technology, which he published widely around “The Bio Revolution”, as well as creating patient benefits from ecosystem-wide, cross-industry collaboration (e.g., in the context of public-private partnerships or industry fora he helped create like in Medical Affairs or Regulatory Affairs). Further, Matthias has served as advisor and speaker at high-profile science events, including the Lindau Nobel Laureate Meetings and Global Biotech Revolution’s GapSummit for young researchers.

Matthias was a Postdoctoral Fellow at the Center for Molecular Neurobiology Hamburg (ZMNH) and holds a Ph.D. based on his work in molecular biology and bioinformatics from the University of Bochum (Germany) where he also earned his MSc in Biochemistry. He is founding member of the Competence Center Biointelligence e.V. and has led the jury of the Science4Life e.V. startup competition for many years.

Dr Craig Johnstone Chief Operating Officer

Dr Craig Johnstone (born in 1970, British citizen) was appointed Chief Operating Officer and Member of the Management Board of Evotec on 01 January 2019. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency. From April 2015, Dr Johnstone was Directeur General and Site Head, Evotec (France) SAS, and from January 2017, he was appointed Global Head, Integrated Drug Discovery. Dr Johnstone is a successful drug discovery leader with over 20 years’ experience particularly in the areas of diabetes, inflammation and oncology. Between 1994 and 2012, Dr Johnstone served in a number of project, function, matrix and leadership roles at AstraZeneca, Prosidion and Rapier Research where he led teams and groups, which discovered numerous candidate drugs for clinical development including AZD1656, which reached PhIIb for Type II Diabetes. During this time, Dr Johnstone also developed expertise in LEAN-inspired process excellence in drug discovery and developed a keen interest in the interface between creativity, innovation and process improvement to deliver the highest performance drug discovery, advising teams and implementing multi-site, international change initiatives to drive performance. Dr Johnstone is a Fellow of the Royal Society of Chemistry and Chartered Chemist (FRSC CChem) and holds BSc in Chemistry and a PhD in organic and organometallic synthesis and is an accredited LEAN Sigma Black Belt. He has published more than 70 patents and papers in drug discovery, medicinal and synthetic chemistry, innovation and LEAN methods applied to the inventive processes of drug discovery. Dr Johnstone does not hold any memberships in supervisory bodies.

Laetitia Rouxel Chief Financial Officer

Laetitia Rouxel (born in 1973, French citizen) joined Evotec as Chief Financial Officer and Member of the Management Board on 01 April 2023. Rouxel has more than 25 years of finance experience in various sectors such as Life Sciences, Food, Cosmetics and Building industry. A graduate of the French Business school ISG, she started her career with finance and commercial roles in the Pharma industry at Pfizer and J&J. She went on to work for the French multinational food-products corporation Danone, where she covered various leading Finance positions in multiple regions for R&D, Medical and Baby Nutrition based in France and in the Netherlands. She then joined the beauty company Coty in Switzerland, where she became divisional CFO. Before joining Evotec, she was Global CFO of Wavin, a solutions leader for the building and infrastructure industry.

Last updated: April 2023

Responsibilities of the Management Board

The Management Board of Evotec SE manages the Company on its own responsibility and represents Evotec SE in transactions with third parties. The Management Board develops the Company strategy, agrees it with the Supervisory Board and ensures its implementation. The Management Board’s actions and decisions are guided by the Company’s interests. It is committed to the target of sustainably increasing enterprise value, while taking the interests of shareholders, employees and other stakeholders into account. The members of the Management Board are jointly responsible for the entire management of the Company and decide on fundamental questions of Company policy and strategy, as well as on the annual and long-term planning.

Members of the Management Board

In addition to the Chair, the Management Board of Evotec SE consists of four further members. The Chair coordinates the work of the Management Board members. New Management Board members are appointed for a maximum term of three years, in accordance with recommendation B.3 of the Code. Contracts may be renewed for up to five years, however, as currently agreed with the Chief Executive Officer, the Chief Scientific Officer and since January 2022 with the Chief Operating Officer. The contract with Dr Craig Johnstone, Chief Operating Officer, was extended with effect from 1 January 2022 for a further five years until 31 December 2026. Dr Matthias Evers was appointed as the new Chief Business Officer for three years with effect from 1 May 2022. This Management Board position was created to reflect the Company’s growth. The contract with Dr Cord Dohrmann, Chief Scientific Officer, was also extended early with effect from 1 September 2022 for a further five years until 31 August 2027. Members of the Management Board may be re-elected or dismissed early for good reason. The members of the Evotec SE Management Board do not hold more than three Supervisory Board seats in publicly listed companies outside the Group or on supervisory boards that make comparable demands. Information about the individual board seats and professional responsibilities of the Management Board members can be found on page 142f of the Annual Report 2022.

Please find further information to all Management Board Members under this link.

Diversity within the Management Board

With regard to the diversity of the Management Board it should be borne in mind that the Supervisory Board selects the Management Board members on the basis of their qualifications and professional background (“thought diversity”), also in view of the seven diversity dimensions defined in the Diversity Charta that Evotec has signed. In accordance with Section 111 (5) AktG the Supervisory Board of Evotec SE defined a quota of female members of the Management Board for the first time in 2015. Given that the four Management Board members with ongoing contracts were all male at the time, this quota was set at 0%. This quota was confirmed in 2017 in view of the terms of the contracts with the current active Management Board members, because no changes in the composition of the Management Board were planned. When deciding whether to renew the contracts with existing Management Board members and to expand the Management Board, the Supervisory Board considered increasing the quota defined for female members, but reserved the right to make its decision based solely on qualifications and performance. The Supervisory Board has now appointed Laetitia Rouxel to succeed Enno Spillner as the new Chief Financial Officer as of 1 April 2023. The Supervisory Board will deal with an increase in the target for the proportion of women on the Executive Board in one of its next meetings. Three of the five current Management Board members do not come from Germany.

An age limit has been set for Management Board members in accordance with recommendation B.5 of the Code. Pursuant to Section 1 (4) of the Rules of Procedure for the Supervisory Board of Evotec SE, the Supervisory Board ensures that no member of the Management Board is older than 65 years of age when appointed.

Responsibilities within the Management Board

Responsibilities within the Management Board in 2022 were divided according to functional criteria, on the basis of Rules of Procedure. The Chief Executive Officer is responsible for coordinating the Management Board and for Investor Relations, ESG and Public Relations, Corporate Communications, Human Resources, Academic Bridges and the Infectious Diseases Strategy. The Chief Business Officer is responsible for Corporate Development and Strategic Planning, Global Business Development, Global Strategic Alliances and Partnerships, Global Information Technology and Security, Global Research Technology and Strategic Marketing. The Chief Financial Officer is in charge of Finance, Controlling, Taxes, Legal & Compliance, Insurance, Risk Management and Internal Audit, and the Export Compliance Office, and exercises the function of the Chief Export Control Officer (CECO). The Chief Operating Officer is responsible for the Drug Discovery and Development segment, Global Biologics, Gene Therapy, Clinical Development, Environment, Health & Safety, Quality Management, and Supply Chains, including purchasing, logistics, facility management and technology. The Chief Scientific Officer is responsible for the Research & Development segment, Cell Therapies, EVOgnostics, Innovative Developments and Joint Strategies, EVT Equity and Operational Venture Capital and Intellectual Property/Patents (EVT Innovate).

As a rule, each individual Management Board member is responsible for managing their own area of responsibility autonomously. Activities and transactions in any single area of responsibility that are of exceptional importance for the Company or which entail an exceptional risk require the prior approval of the entire Management Board. Further details are defined in the Rules of Procedure for the Management Board.

Management Board meetings

Management Board meetings are convened by the Chair of the Management Board (CEO). Each Management Board member can require an extraordinary Management Board meeting to be convened, in addition to the regular Management Board meetings. The Chair of the Management Board (CEO) chairs the Management Board meetings and coordinates the work of the individual members. Individuals who are not Management Board members may be invited to advise at a Management Board meeting by resolution of the Management Board.

Brief minutes are to be taken of key negotiations and resolutions. Management Board resolutions are generally taken in meetings. However, they may also be taken without a meeting; in writing, by electronic means or by phone. The Management Board is quorate when the majority of its members vote on the resolution. As a rule, Management Board resolutions are passed by a simple majority. If the vote is tied, the Chair has the casting vote.

Succession Plan for Management Board Members

The Supervisory Board and the Management Board have taken care of long-term succession planning. It reflects the requirements of the German Stock Corporation Act (AktG) and the Code, as well as the diversity concept for the composition of the Management Board adopted by the Supervisory Board. Taking the concrete qualification requirements and the criteria mentioned into account, the Nomination Committee of the Supervisory Board prepares an ideal profile on the basis of which the Nomination Committee draws up a short list of available candidates. Interviews are held with these candidates. A recommendation is then made to the Supervisory Board for resolution. If necessary, the Supervisory Board and/or the Nomination Committee are supported by external advisers to develop the requirement profile and select the candidates.

Supervisory Board

As stipulated in the current articles of association of Evotec SE, the Company’s Supervisory Board consists of six members, who are elected by simple majority voting by shareholders at the Annual General Meeting. The Supervisory Board members are elected for five years and may be re-elected for a maximum of two full terms of office. As of the next election, a shortening of the five-year term of office is planned, as well as a staggering of the terms of office and a limitation of the total time in years instead of terms of office. The term of office of all the Supervisory Board members ends at the close of the Annual General Meeting 2024 that passes a resolution on discharging the Supervisory Board members of liability for the Company’s 2023 financial year.

Prof. Dr Iris Löw-Friedrich

Chief Medical Officer of UCB S.A., Chairperson of the Supervisory Board of Evotec SE

Roland Sackers

Chief Financial Officer and Managing Director of QIAGEN N.V., Vice Chairman of the Supervisory Board of Evotec SE

Camilla Macapili Languille

Head of Life Sciences, Mubadala Investment Company

Dr Mario Polywka

Consultant

Dr Elaine Sullivan

Non-Executive Director at the IP Group plc, hVIVO plc and Nykode Therapeutics ASA

Dr Constanze Ulmer-Eilfort

Partner of the law firm Peters, Schönberger & Partner (PSP München)

Prof. Dr Iris Löw-Friedrich

Chief Medical Officer of UCB S.A., Chairperson of the Supervisory Board of Evotec SE

Roland Sackers

Chief Financial Officer and Managing Director of QIAGEN N.V., Vice Chairman of the Supervisory Board of Evotec SE

Camilla Macapili Languille

Head of Life Sciences, Mubadala Investment Company

Dr Mario Polywka

Consultant

Dr Elaine Sullivan

Non-Executive Director at the IP Group plc, hVIVO plc and Nykode Therapeutics ASA

Dr Constanze Ulmer-Eilfort

Partner of the law firm Peters, Schönberger & Partner (PSP München)

Prof. Dr Iris Löw-Friedrich Chief Medical Officer of UCB S.A., Chairperson of the Supervisory Board of Evotec SE

Prof. Dr Iris Löw-Friedrich (born in 1960, German citizen) was appointed Member of the Supervisory Board on 17 June 2014 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2019 on 19 June 2019 for a term of five years. Since 15 June 2021 she has been serving as chairwoman of the Supervisory Board. Her current term will expire at the end of the Annual General Meeting held in the year 2024.

Since March 2008, Prof. Dr Iris Löw-Friedrich is serving as Chief Medical Officer and Executive Vice President Development and Medical Practices of UCB S.A., Brussels (Belgium).

From 2001 to 2009, Prof. Dr Löw-Friedrich was a member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen.

From 1992 to 2000, Prof. Dr Löw-Friedrich held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion Roussel/Aventis, Bridgewater, NJ, USA.

Since April 2014, she has been Member of the Board of Directors at TransCelerate BioPharma Inc (Chairman of the Board of Directors from September 2015 until September 2017). TransCelerate BioPharma Inc is a non-profit organisation with membership of 20 major life science companies, including UCB. Since April 2019, she is also a member of the Board of Directors of PhRMA Foundation in Washington DC (US).

Since May 2016, Prof. Dr Löw-Friedrich has been serving as Member of the Supervisory Board of Fresenius SE & Co. KGaA. Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000.

She studied medicine at the University of Frankfurt/Main, receiving her doctorate from this university in 1985.

Prof Dr Iris Löw-Friedrich is independent in the opinion of the Company. Her position on the Executive Board of UCB S.A., which has a business relationship with Evotec SE, does not constitute dependency. Business relationships constitute a material and prolonged conflict of interest only in exceptional cases. The Supervisory Board has no influence on the volume of orders or the continuation or expansion of business relationships. This is the responsibility of the Management Board of Evotec SE, which not only represents the Company (section 78 of the German Stock Corporation Act (AktG)), but also makes decisions on these matters under its own responsibility (section 76, paragraph 1 of the German Stock Corporation Act (AktG)). There is also no intersecting executive body position.

Latest update: June 2022

Roland Sackers Chief Financial Officer and Managing Director of QIAGEN N.V., Vice Chairman of the Supervisory Board of Evotec SE

Mr Roland Sackers (born in 1968, German citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. Since 15 June 2021 he is Vice Chairman of the Supervisory Board. His current term will expire at the end of the Annual General Meeting held in the year 2024.

Mr Sackers has been serving as Chief Financial Officer of QIAGEN N.V. since January 2004. In this position, he is responsible for developing and executing the long-term financial planning, which is the foundation for the company’s accelerated growth strategy.

Prior to joining QIAGEN in 1999, Mr Sackers served as Auditor at the auditing company Arthur Andersen.

Mr Sackers received his master’s degree in Business Administration from the University of Münster.

He represents QIAGEN as board member of BIO Deutschland e.V. Mr Roland Sackers (CFO of Qiagen N.V.) is independent. Qiagen N.V. has no significant business relationship with Evotec SE, and no other circumstances leading to dependency are apparent.

Latest update: June 2021

Camilla Macapili Languille Head of Life Sciences, Mubadala Investment Company

Mrs Camilla Macapili Languille (born 1983, Canadian citizen) was appointed Member of the Supervisory Board on 22 June 2022.

Camilla Macapili Languille is an investment expert with some 20 years of experience in business development, asset management and M&A in Europe, North America and Middle East and North Africa (MENA). She has worked in various areas of corporate finance and principal investment, with a focus on healthcare, technology and industrial companies.

Camilla Macapili Languille leads the Life Sciences investments team at Mubadala Investment Company ("MIC"), a sovereign wealth fund based in Abu Dhabi with total assets of some USD 280 billion. This team invests in the international healthcare industry in the fields of pharmaceuticals, biotechnology, medical devices, life science tools and diagnostics, healthcare IT, and services across various assets with a focus on private equity. She is currently a member of the Direct Investments Committee of Mubadala and serves on the boards of PCI Pharma, Envirotainer, Norstella and Evotec. She has previously served on the boards of Envision Pharma Group, Rodenstock, and Outset Medical.

Before founding the Life Sciences investment team, Camilla Macapili Languille managed MIC’s investments in Advanced Micro Devices (“AMD”) and Globalfoundries and was responsible for business development in the technology sector. She also led MIC’s investments in two power plants in Oman and Algeria, a goldmine in Colombia and a district cooling plant, Tabreed, and was responsible for business development for MIC in the field of conventional energy.

Before joining Mubadala, Camilla Macapili Languille worked in M&A for Daiwa Capital and Société Générale in Paris, France, where she specialised in cross-border transactions in various sectors. She also worked as an investment manager at the London headquarters of the Virgin Group, where she managed the special situations portfolio, was involved in the establishment of Virgin Healthcare, and was a director of several companies

Camilla Macapili Languille began her career in healthcare M&A at JPMorgan in New York and London, where she focused on pharma, medtech and biotech.

Camilla Macapili Languille holds a Bachelor of Economics & Political Science degree from Columbia University, which she completed summa cum laude in 2004. She grew up in an international environment and has lived in 14 countries on four continents. She speaks fluent English and French.

Her long-standing, wide-ranging experience in the pharmaceutical and biotech sectors mean she has extensive knowledge of the industry. Her particular investment expertise makes Ms Macapili Languille an ideal addition to the range of competences represented on the potential Supervisory Board of Evotec SE.

Latest update: April 2023

Dr Mario Polywka Consultant

Dr Mario Polywka (born in 1963, British citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. His current term will expire at the end of the Annual General Meeting held in the year 2024.

Dr Polywka retired from the Management Board of Evotec AG effective 31 December 2018. Until then, he served as member of the Management Board and Chief Operating Officer of Evotec AG since 28 November 2007.

In 1991, he was a founding chemist of Oxford Asymmetry International plc (OAI), became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr Polywka was appointed Chief Operating Officer and in 2000 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000 he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr Polywka ran a number of spin-out companies from Oxford and Southampton Universities.

Dr Polywka received his Bachelor’s degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with post-doctoral studies on the biosynthesis of Penicillin with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994.

Dr Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis.

In May 2017, Dr Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc. and in September 2017, Dr Mario Polywka also joined the Board of Directors of Exscientia Ltd. In September 2019, Dr Polywka was appointed Non-Executive Director at the UK biotech company Orbit Discovery, and has accepted a position as Senior Advisor with MCF Corporate Finance. He has served as Non-Executive Director at UK based company C4X Discovery Holdings PLC since December 2021.

Dr Mario Polywka, who served as COO of Evotec until 31 December 2018 and who was elected to the Supervisory Board on the recommendations of a group of shareholders who together hold more than 25% of the total number of voting rights in the Company, is regarded as not independent.

Latest update: June 2022

Dr Elaine Sullivan Non-Executive Director at the IP Group plc, hVIVO plc and Nykode Therapeutics ASA

Dr Elaine Sullivan (born in 1961, British citizen) was appointed Member of the Supervisory Board on 09 June 2015 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2019 on 19 June 2019 for a term of five years. Her current term will expire at the end of the Annual General Meeting held in the year 2024.

Elaine is a Non-Executive Director at the IP Group plc, hVIVO plc and Nykode Therapeutics ASA and chair of the R&D committee. She has over 25 years of international experience working in the pharmaceutical and biotech industry. She co-founded and was CEO of Carrick Therapeutics, a European oncology company, which raised € 95 m in Series A funding. Elaine was the CEO of Keltic Pharma Therapeutics, a company with a focus on severe asthma, neuropsychiatric disorders, and malaria.

Elaine has worked as part of the most senior R&D management teams at Eli Lilly and AstraZeneca. She served as Vice President Global External Research and Development at Eli Lilly & Company, Inc., Indianapolis, USA, where she led a global workforce delivering access to business-critical external innovation. She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly’s Capital Fund partners.

Prior to joining Eli Lilly, Elaine was Vice President R&D, New Opportunities at AstraZeneca. In this role, she led the virtual therapy disease function which pinpointed new disease areas and created new therapeutic applications for multiple molecular entities and advanced them into the clinic. As Vice-President, Science & Technology at AstraZeneca, Elaine was focused on acquiring new technologies. She has successfully delivered over 250 collaborations and transactions including spinouts, joint ventures, strategic partnerships and acquisitions.

Elaine holds a doctorate in Molecular Biology and Virology from the University of Edinburgh, UK, and a bachelor’s degree in Molecular Biology from the University of Glasgow, UK.

Dr Elaine Sullivan (the former CEO of Carrick Therapeutics Ltd) is independent. Evotec SE holds approximately 4.5% of the shares in Carrick Therapeutics Ltd., and it is not a significant partner of Carrick Therapeutics Ltd. at present.

Therefore, for two reasons there is no conflict of interest that could hinder the position of independence:

Evotec SE's participation rights in Carrick Therapeutics Ltd. are exercised by the Management Board of Evotec SE on its own responsibility pursuant to section 76 paragraph 1 of the German Stock Corporation Act (AktG). In particular, a member of the Supervisory Board has no influence on the voting on the resolutions of the shareholders of Carrick Therapeutics Ltd. (e.g. on any formal approval).
There is also no intersecting executive body position, nor are there any other significant connections to members of the company's Management Board through their involvement in other companies or organisations.

Latest update: June 2023

Dr Constanze Ulmer-Eilfort Partner of the law firm Peters, Schönberger & Partner (PSP München)

Dr Ulmer-Eilfort (born in 1962, German citizen) has more than twenty years’ experience in advising high-tech, pharmaceutical and media companies on the protection and marketing of their intellectual property rights. As a Partner with PSP München, she advises on a wide range of agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions.

Previously, Dr Ulmer-Eilfort was a Partner with the international law firm Baker McKenzie where she was also a member of the Global Executive, chairing the Global Financial Committee and overseeing the budgeting process and budget controls worldwide.

Dr Ulmer-Eilfort’s leadership roles in both management and supervisory functions as well as her specialisation in the protection and marketing of intellectual property and corporate governance are an ideal qualification for her membership of the Supervisory Board of Evotec SE.

Dr Ulmer-Eilfort is to be considered as independent as she has no business relationship with Evotec SE and no other circumstances leading to dependency are apparent. She is chairwoman of the advisory committee of S4DX GmbH. Since June 2023 she is member of the supervisory board of Affimed N.V.

Otherwise she is not a member of any further statutory supervisory boards or similar domestic or foreign supervisory boards of commercial entities in accordance with Sec. 125 para. 1 sentence 5 AktG and recommendation C.14 of the German Corporate Governance Code as amended on 16 December 2019.

Latest update: June 2023

Please find more information about all current Supervisory Board members under this link.

Tenure and committee membership on the Supervisory Board

as of June 2023

Initial appointment to the Supervisory Board

End of tenure

Audit and Compliance Committee

Renumeration and Nomination Committee

ESG Committee

Prof Dr Iris Löw-Friedrich (Chairwoman of the Supervisory Board)

2014

2024

X (Chair)

Roland Sackers (Vice Chairman of the Supervisory Board)

2019

2024

X (Chair)

Camilla Macapili Languille¹⁾

2022

2024

Dr Mario Polywka

2019

2024

Dr Elaine Sullivan

2015

2024

Dr Constanze Ulmer-Eilfort

2021

2024

X (Chair)

Prof Dr Iris Löw-Friedrich (Chairwoman of the Supervisory Board)
Initial appointment to the Supervisory Board	2014
End of tenure	2024
Audit and Compliance Committee
Renumeration and Nomination Committee	X (Chair)
ESG Committee
Roland Sackers (Vice Chairman of the Supervisory Board)
Initial appointment to the Supervisory Board	2019
End of tenure	2024
Audit and Compliance Committee	X (Chair)
Renumeration and Nomination Committee	X
ESG Committee
Camilla Macapili Languille¹⁾
Initial appointment to the Supervisory Board	2022
End of tenure	2024
Audit and Compliance Committee
Renumeration and Nomination Committee
ESG Committee	X
Dr Mario Polywka
Initial appointment to the Supervisory Board	2019
End of tenure	2024
Audit and Compliance Committee	X
Renumeration and Nomination Committee
ESG Committee
Dr Elaine Sullivan
Initial appointment to the Supervisory Board	2015
End of tenure	2024
Audit and Compliance Committee
Renumeration and Nomination Committee	X
ESG Committee	X
Dr Constanze Ulmer-Eilfort
Initial appointment to the Supervisory Board	2021
End of tenure	2024
Audit and Compliance Committee	X
Renumeration and Nomination Committee
ESG Committee	X (Chair)

Composition of the Supervisory Board: Diversity and independency criteria fullfilled

In accordance with the recommendations of the Code, the members of the Evotec Supervisory Board were selected regardless of their gender, nationality and age, according to their qualifications, professional experience, ability and independence. It should be noted, however, that the Supervisory Board has set an age limit and determined that potential candidates may not be older than 72 years of age when they are proposed for election. In addition, the Supervisory Board currently has defined two full periods of office as the regular limit for membership of the Supervisory Board but plans to adjust this as well with the planned shortening of terms of office at the 2024 Annual General Meeting.

An appropriate proportion of women is also required. To this end the Supervisory Board has set a gender quota requiring a respective proportion of women and men of at least 30%.

The Supervisory Board has also set concrete targets for its composition and competences and drawn up a Competence and Specialist Knowledge Profile that reflects the Company’s specific situation. Taking the company-specific situation into account, these targets and competence profiles require a majority of the Supervisory Board members to have national and international experience in (i) research and development, (ii) finance, capital markets, law, corporate governance, (iii) marketing, sales and operations, (iv) (public) healthcare and (v) expertise in sustainability topics that are relevant to the Company. Potential conflicts of interest should also be averted by examining potential candidates for the Supervisory Board very closely when they are selected. Furthermore, the Supervisory Board should be composed in such a way that the majority of its members are independent and collectively have the knowledge, skills and functional experience to carry out their tasks properly.

The composition of the Supervisory Board currently meets these targets and competence profiles: From their work in various international companies, all the members have an extensive international professional background. All the members are considered to be independent in accordance with the two-dimensional evaluation criteria of the German Corporate Governance Code, three different nationalities are represented and four members are female. Evotec strives for diversity of opinion, which is ensured by the composition of an internationally experienced Supervisory Board with a broad range of skills.

The current composition of the Supervisory Board conforms to the competence profile as described and last confirmed in 2022 when re-elections to the Supervisory Board were held.

Prof Dr Iris Löw-Friedrich (Chair)

Roland Sackers (Deputy Chair)

Camilla Macapili Languille

Dr Mario Polywka

Dr Elaine Sullivan

Dr Constanze Ulmer-Eilfort

Independent Supervisory Board members

X¹⁾

X²⁾

X³⁾

Research and development

Finance and financial markets

X⁴⁾

X⁵⁾

Legal and compliance

ESG and sustainability

Marketing, sales and operations

Healthcare and public health

Age of Supervisory Board candidate does not exceed 72 years at the time of proposal

X
(1960)

X
(1968)

X
(1983)

X
(1963)

X
(1962)

X
(1961)

Regional experience

EU, USA, Asia

EU, USA

EU, USA, MENA

EU, USA

EU, USA, Asia

Female Supervisory Board members

Terms of office starts (max. 2 full terms of office)

X
(2014)

X
(2019)

X
(2022)

X
(2019)

X
(2021)

X
(2015)

	Independent Supervisory Board members
Prof Dr Iris Löw-Friedrich (Chair)	X¹⁾
Roland Sackers (Deputy Chair)	X
Camilla Macapili Languille	X²⁾
Dr Mario Polywka	X³⁾
Dr Elaine Sullivan	X
Dr Constanze Ulmer-Eilfort	X
	Research and development
Prof Dr Iris Löw-Friedrich (Chair)	X
Roland Sackers (Deputy Chair)	-
Camilla Macapili Languille	-
Dr Mario Polywka	X
Dr Elaine Sullivan	-
Dr Constanze Ulmer-Eilfort	X
	Finance and financial markets
Prof Dr Iris Löw-Friedrich (Chair)	-
Roland Sackers (Deputy Chair)	X⁴⁾
Camilla Macapili Languille	X
Dr Mario Polywka	X⁵⁾
Dr Elaine Sullivan	X
Dr Constanze Ulmer-Eilfort	-
	Legal and compliance
Prof Dr Iris Löw-Friedrich (Chair)	-
Roland Sackers (Deputy Chair)	X
Camilla Macapili Languille	-
Dr Mario Polywka	-
Dr Elaine Sullivan	X
Dr Constanze Ulmer-Eilfort	-
	ESG and sustainability
Prof Dr Iris Löw-Friedrich (Chair)	X
Roland Sackers (Deputy Chair)	X
Camilla Macapili Languille	X
Dr Mario Polywka	-
Dr Elaine Sullivan	X
Dr Constanze Ulmer-Eilfort	-
	Marketing, sales and operations
Prof Dr Iris Löw-Friedrich (Chair)	X
Roland Sackers (Deputy Chair)	-
Camilla Macapili Languille	-
Dr Mario Polywka	X
Dr Elaine Sullivan	-
Dr Constanze Ulmer-Eilfort	X
	Healthcare and public health
Prof Dr Iris Löw-Friedrich (Chair)	X
Roland Sackers (Deputy Chair)	-
Camilla Macapili Languille	X
Dr Mario Polywka	-
Dr Elaine Sullivan	-
Dr Constanze Ulmer-Eilfort	X
	Age of Supervisory Board candidate does not exceed 72 years at the time of proposal
Prof Dr Iris Löw-Friedrich (Chair)	X (1960)
Roland Sackers (Deputy Chair)	X (1968)
Camilla Macapili Languille	X (1983)
Dr Mario Polywka	X (1963)
Dr Elaine Sullivan	X (1962)
Dr Constanze Ulmer-Eilfort	X (1961)
	Regional experience
Prof Dr Iris Löw-Friedrich (Chair)	EU, USA, Asia
Roland Sackers (Deputy Chair)	EU, USA
Camilla Macapili Languille	EU, USA, MENA
Dr Mario Polywka	EU, USA
Dr Elaine Sullivan	EU
Dr Constanze Ulmer-Eilfort	EU, USA, Asia
	Female Supervisory Board members
Prof Dr Iris Löw-Friedrich (Chair)	X
Roland Sackers (Deputy Chair)	-
Camilla Macapili Languille	X
Dr Mario Polywka	-
Dr Elaine Sullivan	X
Dr Constanze Ulmer-Eilfort	X
	Terms of office starts (max. 2 full terms of office)
Prof Dr Iris Löw-Friedrich (Chair)	X (2014)
Roland Sackers (Deputy Chair)	X (2019)
Camilla Macapili Languille	X (2022)
Dr Mario Polywka	X (2019)
Dr Elaine Sullivan	X (2021)
Dr Constanze Ulmer-Eilfort	X (2015)

1) Management Board member of UCB: the commercial relationship with UCB as a customer of Evotec is considered to be immaterial (approx. 0.5% of Group revenue in 2022)

2) Head of Life Sciences at Mubadala Investment Company: Mubadala Investment Company holds some 7% of the shares in Evotec, but does not exercise control within the meaning of C.9 GCGC

3) The cooling-off period defined in C.7 DCGK ended at the close of 2020

4) Experience of auditing and accounting

5) Experience of accounting

The members of the Supervisory Board attend any training courses necessary for the performance of their duties of their own accord.

Election of Supervisory Board Members

The Supervisory Board Chair coordinates the work of the Supervisory Board and represents the Supervisory Board externally. The Supervisory Board Chair is available to shareholders to discuss topics specific to the Supervisory Board.

The Supervisory Board appoints and dismisses the members of the Management Board and advises and supervises the Management Board on the management of the Company. Frank discussions take place between the Management Board and Supervisory Board, which both parties ensure remain confidential. The Supervisory Board, in particular the Supervisory Board Chair, are in regular contact with the Management Board. The Management Board reported to the Supervisory Board in numerous conference calls, which were arranged as needed, and provided ongoing written and oral reports and information in the form of detailed analysis of the Company’s operating business and other topics such as strategy, planning, risk management and compliance management systems.

In line with recommendation D.7 of the Code, the Supervisory Board met regularly for the scheduled Supervisory Board meetings without the Management Board.

More information about the Supervisory Board can be found in the Declaration of Corporate Management as well as in the Supervisory Board Report. Please find the respective documents for Download below.

Downloads

Declaration of Corporate Management 2022PDF, 271.3 KB

Declaration of Corporate Management 2021PDF, 401.4 KB

Former Declarations of Corporate Management (2013-2020)PDF, 2.0 MB

Supervisory Report 2022PDF, 615.9 KB

Supervisory Board meetings

The articles of association provide for Supervisory Board resolutions to be adopted in meetings as a rule. However, meetings may be held and resolutions adopted in writing, by phone, or by means of electronic or other communications technologies, if the Supervisory Board Chair so decides in any specific case. The articles of association also stipulate that the Supervisory Board is quorate when more than half its members take part in the resolution in person or by voting in writing or any other permissible form. Otherwise, the Supervisory Board is to be convened again, with a period of two weeks between the date of the invitation and the meeting. The Supervisory Board is then quorate when at least three members take part in the resolution. Absent members can take part in the Supervisory Board resolution by casting their vote in writing. Supervisory Board resolutions are passed by a simple majority of votes cast. The Supervisory Board has also adopted Rules of Procedure (see www.evotec.com; heading IR & ESG).

It is ensured that every Supervisory Board member has sufficient time for the exercise of their duties. None of the Supervisory Board members has a seat on more than five supervisory boards of publicly listed entities outside the Group. Equally, none of the Supervisory Board members with a seat on the management board of a publicly listed entity holds more than two supervisory board seats on publicly listed entities within the Group or has comparable functions, nor chairs the supervisory board of any publicly listed entity outside the Group.

The Supervisory Board was not aware of any conflicts of interests affecting its members in 2022.

The Supervisory Board has its own internal rules of procedure. Please find below the Rules of Procedure of the Supervisory Board for Download.

Downloads

Rules of Procedure of the Supervisory BoardPDF, 114.5 KB

Supervisory Board committees

(as of June 2023)

Audit and Compliance Committee

Remuneration and Nomination Committee

ESG

Prof. Dr Iris Löw-Friedrich (Chairperson)

X (Chair)

Roland Sackers (Vice Chairman)

X (Chair)

Camilla Macapili Languille

Dr Mario Polywka

Dr Elaine Sullivan

Dr Constanze Ulmer-Eilfort

X (Chair)

Prof. Dr Iris Löw-Friedrich (Chairperson)
Audit and Compliance Committee
Remuneration and Nomination Committee	X (Chair)
ESG
Roland Sackers (Vice Chairman)
Audit and Compliance Committee	X (Chair)
Remuneration and Nomination Committee	X
ESG
Camilla Macapili Languille
Audit and Compliance Committee
Remuneration and Nomination Committee
ESG	X
Dr Mario Polywka
Audit and Compliance Committee	X
Remuneration and Nomination Committee
ESG
Dr Elaine Sullivan
Audit and Compliance Committee
Remuneration and Nomination Committee	X
ESG	X
Dr Constanze Ulmer-Eilfort
Audit and Compliance Committee	X
Remuneration and Nomination Committee
ESG	X (Chair)

The activities of the Supervisory Board comply with the Corporate Governance Code

An important part of the Supervisory Board work takes place in committees. In accordance with the requirements of the German Stock Corporation Act (AktG) and the recommendations of the Code, the Supervisory Board of Evotec SE has formed an Audit and Compliance Committee, a Remuneration and Nomination Committee, and for the first time in 2022 an ESG Committee. The committees are staffed in accordance with the Code.

The Audit and Compliance Commitee

The three-member Audit and Compliance Committee supports the Supervisory Board with its independent supervision of financial reporting and its audit as well as non-financial reporting. The Audit and Compliance Committee particularly reviews the financial reporting processes, the effectiveness of the internal control system and the audit of the financial statements. This includes discussing with the Management Board the interim and half-year reports and the risk management and compliance management systems, including IT and cyber security. The Audit and Compliance Committee also reviews any transactions with related parties. In addition, the Audit and Compliance Committee discusses with the appointed auditors the individual audit stages and procedures in the context of the audit engagement assigned by the Supervisory Board, including the independence and quality of the auditors, any additional services provided by the auditors, the appointment of the auditors, the definition of the focal points of the audit, the fee agreement and compliance topics. In the context of preparing and carrying out the audit the Audit and Compliance Committee communicates regularly with the auditors without the involvement of the Management Board.

Please find below the Audit Committee’s charter for download.

Downloads

Audit & Compliance Committee Charter (November 2021)PDF, 417.2 KB

The Remuneration and Nomination Committee

The Remuneration and Nomination Committee is primarily responsible for preparing the appointment of Management Board members and preparing the remuneration system for the Management Board, including the Share Performance Plan. Resolutions on these topics are taken by the full Supervisory Board.

Please find below the charter of the Remuneration and Nomination Committee for download.:

Downloads

Remuneration and Nomination Committee Charter (November 2021)PDF, 200.8 KB

The ESG Committee

In view of the increasing importance of environmental, social and governance (ESG) aspects, the Supervisory Board formed an ESG Committee in 2022. It is made up of three Supervisory Board members, who are supported by the CEO, the Global Head of HR and the Head of Global Investor Relations & ESG. Alongside the Management Board the ESG Committee defines on an ongoing basis which priorities Evotec sets in terms of environmental, social and governance policy, and advises on and monitors their implementation.

Please find below the charter of the ESG Committee:

Downloads

ESG Committee Charter (January 2023)PDF, 81.3 KB

Attendance at meetings of the Supervisory Board and its Comittees 2022

Supervisory Board member

Number of Supervisory Board and committee meetings

Attendance

Presence^*

Prof. Dr Iris Löw-Friedrich (Chair)

5+4**

5+4

100%

Roland Sackers
(Vice Chair)¹⁾

5+6+4

100%

Kasim Kutay²⁾

3+1

1+0

25%

Camilla Macapili Languille¹⁾

2+3

100%

Dr Mario Polywka

5+6

100%

Dr. Constanze Ulmer-Eilfort

5+6+3

100%

Dr Elaine Sullivan

5+4+3

5+4+2

75%

Prof. Dr Iris Löw-Friedrich (Chair)
Number of Supervisory Board and committee meetings	5+4**
Attendance	5+4
Presence^*	100%
Roland Sackers (Vice Chair)¹⁾
Number of Supervisory Board and committee meetings	5+6+4
Attendance	5+6+4
Presence^*	100%
Kasim Kutay²⁾
Number of Supervisory Board and committee meetings	3+1
Attendance	1+0
Presence^*	25%
Camilla Macapili Languille¹⁾
Number of Supervisory Board and committee meetings	2+3
Attendance	2+3
Presence^*	100%
Dr Mario Polywka
Number of Supervisory Board and committee meetings	5+6
Attendance	5+6
Presence^*	100%
Dr. Constanze Ulmer-Eilfort
Number of Supervisory Board and committee meetings	5+6+3
Attendance	5+6+3
Presence^*	100%
Dr Elaine Sullivan
Number of Supervisory Board and committee meetings	5+4+3
Attendance	5+4+2
Presence^*	75%

^* ^{Commercially rounded} ^** ^{SB meetings + Committee meetings}
¹⁾ ^{since AGM in June 2022}
²⁾ ^{until AGM in June 2022}

Remuneration of Management and Supervisory Board 2022

Downloads

Remuneration Report 2022 of Evotec SEPDF, 967.0 KB

Disclosure of Management Transactions (Directors' Dealings)

Notification about Directors’ Dealings under article 19 European Market Abuse Regulation (MAR)

Information about the transaction with duty of notification
Description of the financial instrument: Share
ISIN of the financial instrument: DE0005664809

Date

Name

Position

Type

No of items

Price

Total

19 January 2023

Craig Johnstone

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

9,663

EUR 17.94

EUR 173,397.70

19 January 2023

Craig Johnstone

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

9,664

EUR 17.94

EUR 173,415,65

19 January 2023

Cord Dohrmann

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

6,153

EUR 17.94

EUR 110,412.51

19 January 2023

Cord Dohrmann

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

9,230

EUR 17.94

EUR 165,627.74

19 January 2023

Enno Spillner

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

6,394

EUR 17.94

EUR 114,737.13

19 January 2023

Enno Spillner

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

6,394

EUR 17.94

EUR 114,737.13

19 January 2023

Werner Lanthaler

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

26,080

EUR 17.94

EUR 467,992.56

19 January 2023

Werner Lanthaler

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

26,081

EUR 17.94

EUR 468,010.50

14 June 2022

Werner Lanthaler

Member of the Management

Purchase

10,000

EUR 22.69

EUR 226,873.95

14 June 2022

Werner Lanthaler

Member of the Management

Purchase

10,000

EUR 22.86

EUR 228,559.35

21 January 2022

Mario Polywka

Member of the Supervisory Board

Purchase of shares by exercising stock options (Share Performance Plan)

11,938

EUR 35.39

EUR 422,459.56

21 January 2022

Mario Polywka

Member of the Supervisory Board

Exercise against Cash Settlement (Share Performance Plan)

12,000

EUR 35.39

EUR 424,653.60

21 January 2022

Craig Johnstone

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

4,111

EUR 35.39

EUR 145,479.25

21 January 2022

Craig Johnstone

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

4,112

EUR 35.39

EUR 145,514.63

21 January 2022

Cord Dohrmann

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

12,573

EUR 35.39

EUR 444,930.81

21 January 2022

Cord Dohrmann

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

12,639

EUR 35.39

EUR 447,266.40

21 January 2022

Enno Spillner

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

10,452

EUR 35.39

EUR 369,873.29

21 January 2022

Enno Spillner

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

10,507

EUR 35.39

EUR 371,819.61

21 January 2022

Werner Lanthaler

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

42,638

EUR 35.39

EUR 1,508,865.02

21 January 2022

Werner Lanthaler

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

42,857

EUR 35.39

EUR 1,516,614.94

04 January 2022

Werner Lanthaler

Member of the Management

Purchase

10,000

EUR 39.25

EUR 392,479.78

30 August 2021

Mario Polywka

Member of the Supervisory Board

Exercise against Cash Settlement (Share Performance Plan)

20,384

EUR 42.47

EUR 865,612.68

30 August 2021

Cord Dohrmann

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

10,362

EUR 42.47

EUR 440,025.44

30 August 2021

Cord Dohrmann

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

10,547

EUR 42.47

EUR 447,881.52

30 August 2021

Craig Johnstone

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

6,387

EUR 42.47

EUR 271,225.87

30 August 2021

Craig Johnstone

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

6,388

EUR 42.47

EUR 271,268.34

30 August 2021

Enno Spillner

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

8,614

EUR 42.47

EUR 365,796.09

30 August 2021

Enno Spillner

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

8,768

EUR 42.47

EUR 372,335.75

30 August 2021

Werner Lanthaler

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

35,136

EUR 42.47

EUR 1,492,060.78

30 August 2021

Werner Lanthaler

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

35,766

EUR 42.47

EUR 1,518,813.92

29 January 2021

Craig Johnstone

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

10,115

EUR 33.22

EUR 336,010.19

28 January 2021

Werner Lanthaler

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

184,174

EUR 34.64

EUR 6,379,032.25

28 January 2021

Werner Lanthaler

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

193,500

EUR 34.64

EUR 6,702,046.65

28 January 2021

Enno Spillner

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

32,589

EUR 34.64

EUR 1,128,749.35

28 January 2021

Enno Spillner

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

60,000

EUR 34.64

EUR 2,078,154.00

26 January 2021

Craig Johnstone

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

6,000

EUR 29.79

EUR 178,716.00

15 December 2020

Cord Dohrmann

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

111,376

EUR 25.53

EUR 2,843,741.13

07 December 2020

Craig Johnstone

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

4,000

EUR 25.01

EUR 100,058.40

26 November 2020

Cord Dohrmann

Member of the Management

Exercise against Cash Settlement (Stock Option Programme)

32,594

EUR 22.38

EUR 729,535.21

13 November 2020

Mario Polywka

Member of the Supervisory Board

Exercise against Cash Settlement (Share Performance Plan)

107,908

EUR 24.23

EUR 2,614,729.54

02 September 2020

Werner Lanthaler

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

11,576

EUR 22.01

EUR 254,787.76

02 September 2020

Werner Lanthaler

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

11,824

EUR 22.01

EUR 260,246.24

02 September 2020

Werner Lanthaler

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

8,244

EUR 21.8267

EUR 179,939.31

02 September 2020

Werner Lanthaler

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

8,356

EUR 21.8267

EUR 182,383.91

31 August 2020

Werner Lanthaler

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

19,764

EUR 21.1379

EUR 417,769.46

31 August 2020

Werner Lanthaler

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

20,236

EUR 21.1379

EUR 427,746.54

28 August 2020

Werner Lanthaler

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

41,034

EUR 21.1122

EUR 866,318.01

28 August 2020

Werner Lanthaler

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

42,050

EUR 21.1122

EUR 887,768.01

28 August 2020

Cord Dohrmann

Member of the Management

Purchase of shares by exercising stock options (Share Performance Plan)

20,000

EUR 21.1122

EUR 422,244.00

28 August 2020

Cord Dohrmann

Member of the Management

Exercise against Cash Settlement (Share Performance Plan)

31,215

EUR 21.1122

EUR 659,017.32

14 August 2020

Werner Lanthaler

Member of the Management

Purchase

20,000

EUR 21.70

EUR 434,000.00

23 June 2020

Werner Lanthaler

Member of Management

Purchase of Shares by exercising stock options (Share Performance Plan)

40,524

EUR 24.2403

EUR 982,313.92

23 June 2020

Werner Lanthaler

Member of Management

Exercise against cash settlement

Transaction linked to the exercise of share option programmes

41,476

EUR 24.2403

EUR 1,005,390.68

03 June 2020

Cord Dohrmann

Member of Management

Exercise against cash settlement

Transaction linked to the exercise of share option programmes

30,000

EUR 23.3362

EUR 700,086.00

21 February 2020

Cord Dohrmann

Member of Management

Exercise against cash settlement

Transaction linked to the exercise of share option programmes

30,000

EUR 24.9126

EUR 747,378.00

29 January 2020

Craig Johnstone

Member of Management

Exercise against Cash Settlement (Share Performance Plan

1,250

EUR 24.6308

EUR 30,788.50

29 January 2020

Craig Johnstone

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

19,836

EUR 24.6308

EUR 488,576.5488

10 January 2020

Mario Polywka

Member of the Supervisory Board

Exercise against Cash Settlement (Share Performance Plan)

127,155

EUR 22.7879

EUR 2,897,595.42

15 November 2019

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 18.4725

EUR 184,724.80

24 September 2019

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

13,950

EUR 20.4628

EUR 285,456.06

24 September 2019

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

54,263

EUR 20.4628

EUR 1,110,372.9164

24 September 2019

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

71,873

EUR 20.3379

EUR 1,461,745.8867

24 September 2019

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

109,863

EUR 20.3379

EUR 2,234,382.7077

24 September 2019

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

57,167

EUR 20.4628

EUR 1,169,796.8876

23 September 2019

Cord Dohrmann

Member of Management

Purchase of Shares by exercising stock options (Share Performance Plan)

26,900

EUR 20.3379

EUR 547,089.51

20 September 2019

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

27,078

EUR 20.0086

EUR 541,792.8708

20 September 2019

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

14,050

EUR 20.0086

EUR 281,120.83

03 September 2019

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 19.00

EUR 190,000.00

19 August 2019

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 18.866059

EUR 188,660.59

15 August 2019

Cord Dohrmann

Member of Management

Purchase

1,000

EUR 19.0375

EUR 19,037.50

12 July 2019

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Share Performance Plan)

280

EUR 24.40

EUR 6,832.00

12 July 2019

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

290

EUR 24.40

EUR 7,076.00

04 July 2019

Craig Johnstone

Member of Management

Exercise against Cash Settlement (Stock option programme)

7,126

EUR 23.9312

EUR 170,533.7312

03 July 2019

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Share Performance Plan)

55,000

EUR 24.50

EUR 1,347,500.00

03 July 2019

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

84,630

EUR 24.50

EUR 2,073,435.00

31 May 2019

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Stock option programme)

50,000

EUR 19.4458

EUR 972,290.00

29 May 2019

Craig Johnstone

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

7,000

EUR 21.6392

EUR 151,474.40

12 Feb 2019

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Share Performance Plan)

30,000

EUR 19.5429

EUR 586,287.00

12 Feb 2019

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

70,000

EUR 19.5429

EUR 1,368,003.00

11 Feb 2019

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Share Performance Plan)

30,000

EUR 19.2454

EUR 577,362.00

11 Feb 2019

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

70,000

EUR 19.2454

EUR 1,347,178.00

22 Jan 2019

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

50,000

EUR 19.3282

EUR 966,410.00

11 Jan 2019

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Share Performance Plan)

80,190

EUR 19.0599

EUR 1,528,413.38

11 Jan 2019

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

69,810

EUR 19.0599

EUR 1,330,571.62

29 Nov 2018

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Stock option programme)

29,220

EUR 17.6169

EUR 514,765.82

16 November 2018

Mario Polywka

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

216,666

EUR 18.8146

EUR 4,076,484.12

02 October 2018

Mario Polywka

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

75,000

EUR 17.6166

EUR 1,321,245.00

15 September 2017

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Share Performance Plan)

59,905

EUR 17.7711

EUR 1,064,577.75

15 September 2017

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

55,000

EUR 17.7711

EUR 977,410.50

07 September 2017

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

48,883

EUR 16.6007

EUR 811,492.02

04 September 2017

Mario Polywka

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

43,261

EUR 15.5612

EUR 673,193.0732

23 August 2017

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Stock option programme)

132,000

EUR 13.57

EUR 1,791,240.00

23 August 2017

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Stock option programme)

118,000

EUR 13.57

EUR 1,601,260.00

18 August 2017

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Stock option programme)

20,654

EUR 12.639

EUR 261,045.906

18 August 2017

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Stock option programme)

11,940

EUR 12.639

EUR 150,909.66

17 August 2017

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

55,400

EUR 14.5105

EUR 803,881.70

15 August 2017

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

28,000

EUR 12.08

EUR 338,240.00

31 March 2017

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Stock option programme)

31,000

EUR 6.908

EUR 214,148.00

30 March 2017

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Stock option programme)

37,000

EUR 6.6904

EUR 247,544.80

30 March 2017

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Stock option programme)

63,000

EUR 6.6904

EUR 421,495.20

29 March 2017

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

20,000

EUR 7.9329

EUR 158,658.00

29 March 2017

Werner Lanthaler

Member of Management

Exercise against Cash Settlement (Stock option programme)

63,000

EUR 6.7029

EUR 422,282.70

29 March 2017

Werner Lanthaler

Member of Management

Purchase of shares by exercising stock options (Stock option programme)

37,000

EUR 6.7029

EUR 240,007.30

17 February 2017

Mario Polywka

Member of Management

Exercise against Cash Settlement (Share Performance Plan)

52,313

EUR 6.274

EUR 328,211.762

15 February 2017

Cord Dohrmann

Member of Management

Exercise against Cash Settlement (Stock option programme)

50,000

EUR 5.0868

EUR 254,340.00

16 August 2016

Werner Lanthaler

Member of Management

Purchase (Stock option programme)

29,220

EUR 2.65

EUR 77,433.00

29 March 2016

Werner Lanthaler

Member of Management

Purchase

20,000

EUR 3.072342

EUR 61,446.84

15 September 2014

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 3.057655

EUR 30,576.55

24 August 2012

Werner Lanthaler

Member of Management

Purchase

20,000

EUR 2.50

EUR 50,000

29 December 2011

Werner Lanthaler

Member of Management

Purchase

12,000

EUR 2.30

EUR 27,600.00

24 November 2011

ROI Verwaltungsgesellschaft, Roland Oetker

Member of Supervisory Board

Purchase

10,000

EUR 2.23297

EUR 22,329.7

07 September 2011

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 2.248

EUR 22,480.00

18 May 2011

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 2.668616

EUR 26,686.16

04 April 2011

Werner Lanthaler

Member of Management

Loan

150,000

EUR 0,00

11 November 2010

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 2.48

EUR 24,800.00

01 October 2010

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 2.30

EUR 23,000.00

30 September 2010

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 2.36782

EUR 23,678.20

12 May 2010

Werner Lanthaler

Member of Management

Purchase

10,000

Eur 1.95

EUR 19,500.00

12 May 2010

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 1.96

EUR 19,600.00

29 March 2010

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 2.05

EUR 20,500.00

25 January 2010

Werner Lanthaler

Member of Management

Purchase

10,530

EUR 1.90

EUR 20,007.00

26 November 2009

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 1.9927

EUR 19,927.00

22 September 2009

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 1.4400

EUR 14,400.00

21 September 2009

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 1.4500

EUR 14,500.00

02 September 2009

Werner Lanthaler

Member of Management

Purchase

10,000

EUR 1.4900

EUR 14,900.00

01 September 2009

Mario Polywka

Member of Management

Purchase

30,000

GBP 1.345

GBP 40,350.00

27 August 2009

Werner Lanthaler

Member of Management

Purchase

4,000

EUR 1.60

EUR 6,400.00

11 August 2009

Werner Lanthaler

Member of Management

Purchase

25,000

EUR 1.4400

EUR 36,000.00

29 June 2009

Werner Lanthaler

Member of Management

Purchase

11,000

EUR 0.9300

EUR 10,230.00

19 June 2009

Werner Lanthaler

Member of Management

Purchase

15,000

EUR 0.7900

EUR 11,850.00

18 June 2009

Werner Lanthaler

Member of Management

Purchase

3,720

EUR 0.7600

EUR 2,827.20

17 June 2009

Werner Lanthaler

Member of Management

Purchase

4,900

EUR 0.7600

EUR 3,724.00

03 June 2009

Werner Lanthaler

Member of Management

Purchase

13,350

EUR 0.7496629

EUR 10,007.999715

18 May 2009

Werner Lanthaler

Member of Management

Purchase

11,649

EUR 0.65

EUR 7,571.85

15 May 2009

Werner Lanthaler

Member of Management

Purchase

65,351

EUR 0.65

EUR 42,478.15

14 May 2009

Werner Lanthaler

Member of Management

Purchase

31,250

EUR 0.6370585

EUR 19,908.08

13 May 2009

Werner Lanthaler

Member of Management

Purchase

12,329

EUR 0.65

EUR 8,013.85

12 May 2009

Werner Lanthaler

Member of Management

Purchase

37,671

EUR 0.65

EUR 24,486.15

22 April 2009

Werner Lanthaler

Member of Management

Purchase

15,900

EUR 0.66

EUR 10,494.00

16 April 2009

Werner Lanthaler

Member of Management

Purchase

31,000

EUR 0.6474193

EUR 20,070.00

27 March 2009

Werner Lanthaler

Member of Management

Purchase

40,000

EUR 0.831375

EUR 33,255.00

06 March 2009

Werner Lanthaler

Member of Management

Purchase

25,000

EUR 0.7169736

EUR 17,924.34

06 March 2009

Werner Lanthaler

Member of Management

Purchase

3,000

EUR 0.6900

EUR 2,070.00

Expand table

Date	19 January 2023
Name	Craig Johnstone
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	9,663
Price	EUR 17.94
Total	EUR 173,397.70
Date	19 January 2023
Name	Craig Johnstone
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	9,664
Price	EUR 17.94
Total	EUR 173,415,65
Date	19 January 2023
Name	Cord Dohrmann
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	6,153
Price	EUR 17.94
Total	EUR 110,412.51
Date	19 January 2023
Name	Cord Dohrmann
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	9,230
Price	EUR 17.94
Total	EUR 165,627.74
Date	19 January 2023
Name	Enno Spillner
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	6,394
Price	EUR 17.94
Total	EUR 114,737.13
Date	19 January 2023
Name	Enno Spillner
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	6,394
Price	EUR 17.94
Total	EUR 114,737.13
Date	19 January 2023
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	26,080
Price	EUR 17.94
Total	EUR 467,992.56
Date	19 January 2023
Name	Werner Lanthaler
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	26,081
Price	EUR 17.94
Total	EUR 468,010.50
Date	14 June 2022
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase
No of items	10,000
Price	EUR 22.69
Total	EUR 226,873.95
Date	14 June 2022
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase
No of items	10,000
Price	EUR 22.86
Total	EUR 228,559.35
Date	21 January 2022
Name	Mario Polywka
Position	Member of the Supervisory Board
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	11,938
Price	EUR 35.39
Total	EUR 422,459.56
Date	21 January 2022
Name	Mario Polywka
Position	Member of the Supervisory Board
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	12,000
Price	EUR 35.39
Total	EUR 424,653.60
Date	21 January 2022
Name	Craig Johnstone
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	4,111
Price	EUR 35.39
Total	EUR 145,479.25
Date	21 January 2022
Name	Craig Johnstone
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	4,112
Price	EUR 35.39
Total	EUR 145,514.63
Date	21 January 2022
Name	Cord Dohrmann
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	12,573
Price	EUR 35.39
Total	EUR 444,930.81
Date	21 January 2022
Name	Cord Dohrmann
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	12,639
Price	EUR 35.39
Total	EUR 447,266.40
Date	21 January 2022
Name	Enno Spillner
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	10,452
Price	EUR 35.39
Total	EUR 369,873.29
Date	21 January 2022
Name	Enno Spillner
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	10,507
Price	EUR 35.39
Total	EUR 371,819.61
Date	21 January 2022
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	42,638
Price	EUR 35.39
Total	EUR 1,508,865.02
Date	21 January 2022
Name	Werner Lanthaler
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	42,857
Price	EUR 35.39
Total	EUR 1,516,614.94
Date	04 January 2022
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase
No of items	10,000
Price	EUR 39.25
Total	EUR 392,479.78
Date	30 August 2021
Name	Mario Polywka
Position	Member of the Supervisory Board
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	20,384
Price	EUR 42.47
Total	EUR 865,612.68
Date	30 August 2021
Name	Cord Dohrmann
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	10,362
Price	EUR 42.47
Total	EUR 440,025.44
Date	30 August 2021
Name	Cord Dohrmann
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	10,547
Price	EUR 42.47
Total	EUR 447,881.52
Date	30 August 2021
Name	Craig Johnstone
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	6,387
Price	EUR 42.47
Total	EUR 271,225.87
Date	30 August 2021
Name	Craig Johnstone
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	6,388
Price	EUR 42.47
Total	EUR 271,268.34
Date	30 August 2021
Name	Enno Spillner
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	8,614
Price	EUR 42.47
Total	EUR 365,796.09
Date	30 August 2021
Name	Enno Spillner
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	8,768
Price	EUR 42.47
Total	EUR 372,335.75
Date	30 August 2021
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	35,136
Price	EUR 42.47
Total	EUR 1,492,060.78
Date	30 August 2021
Name	Werner Lanthaler
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	35,766
Price	EUR 42.47
Total	EUR 1,518,813.92
Date	29 January 2021
Name	Craig Johnstone
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	10,115
Price	EUR 33.22
Total	EUR 336,010.19
Date	28 January 2021
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	184,174
Price	EUR 34.64
Total	EUR 6,379,032.25
Date	28 January 2021
Name	Werner Lanthaler
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	193,500
Price	EUR 34.64
Total	EUR 6,702,046.65
Date	28 January 2021
Name	Enno Spillner
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	32,589
Price	EUR 34.64
Total	EUR 1,128,749.35
Date	28 January 2021
Name	Enno Spillner
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	60,000
Price	EUR 34.64
Total	EUR 2,078,154.00
Date	26 January 2021
Name	Craig Johnstone
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	6,000
Price	EUR 29.79
Total	EUR 178,716.00
Date	15 December 2020
Name	Cord Dohrmann
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	111,376
Price	EUR 25.53
Total	EUR 2,843,741.13
Date	07 December 2020
Name	Craig Johnstone
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	4,000
Price	EUR 25.01
Total	EUR 100,058.40
Date	26 November 2020
Name	Cord Dohrmann
Position	Member of the Management
Type	Exercise against Cash Settlement (Stock Option Programme)
No of items	32,594
Price	EUR 22.38
Total	EUR 729,535.21
Date	13 November 2020
Name	Mario Polywka
Position	Member of the Supervisory Board
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	107,908
Price	EUR 24.23
Total	EUR 2,614,729.54
Date	02 September 2020
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	11,576
Price	EUR 22.01
Total	EUR 254,787.76
Date	02 September 2020
Name	Werner Lanthaler
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	11,824
Price	EUR 22.01
Total	EUR 260,246.24
Date	02 September 2020
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	8,244
Price	EUR 21.8267
Total	EUR 179,939.31
Date	02 September 2020
Name	Werner Lanthaler
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	8,356
Price	EUR 21.8267
Total	EUR 182,383.91
Date	31 August 2020
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	19,764
Price	EUR 21.1379
Total	EUR 417,769.46
Date	31 August 2020
Name	Werner Lanthaler
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	20,236
Price	EUR 21.1379
Total	EUR 427,746.54
Date	28 August 2020
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	41,034
Price	EUR 21.1122
Total	EUR 866,318.01
Date	28 August 2020
Name	Werner Lanthaler
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	42,050
Price	EUR 21.1122
Total	EUR 887,768.01
Date	28 August 2020
Name	Cord Dohrmann
Position	Member of the Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	20,000
Price	EUR 21.1122
Total	EUR 422,244.00
Date	28 August 2020
Name	Cord Dohrmann
Position	Member of the Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	31,215
Price	EUR 21.1122
Total	EUR 659,017.32
Date	14 August 2020
Name	Werner Lanthaler
Position	Member of the Management
Type	Purchase
No of items	20,000
Price	EUR 21.70
Total	EUR 434,000.00
Date	23 June 2020
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of Shares by exercising stock options (Share Performance Plan)
No of items	40,524
Price	EUR 24.2403
Total	EUR 982,313.92
Date	23 June 2020
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against cash settlement Transaction linked to the exercise of share option programmes
No of items	41,476
Price	EUR 24.2403
Total	EUR 1,005,390.68
Date	03 June 2020
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against cash settlement Transaction linked to the exercise of share option programmes
No of items	30,000
Price	EUR 23.3362
Total	EUR 700,086.00
Date	21 February 2020
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against cash settlement Transaction linked to the exercise of share option programmes
No of items	30,000
Price	EUR 24.9126
Total	EUR 747,378.00
Date	29 January 2020
Name	Craig Johnstone
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan
No of items	1,250
Price	EUR 24.6308
Total	EUR 30,788.50
Date	29 January 2020
Name	Craig Johnstone
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	19,836
Price	EUR 24.6308
Total	EUR 488,576.5488
Date	10 January 2020
Name	Mario Polywka
Position	Member of the Supervisory Board
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	127,155
Price	EUR 22.7879
Total	EUR 2,897,595.42
Date	15 November 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 18.4725
Total	EUR 184,724.80
Date	24 September 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	13,950
Price	EUR 20.4628
Total	EUR 285,456.06
Date	24 September 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	54,263
Price	EUR 20.4628
Total	EUR 1,110,372.9164
Date	24 September 2019
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	71,873
Price	EUR 20.3379
Total	EUR 1,461,745.8867
Date	24 September 2019
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	109,863
Price	EUR 20.3379
Total	EUR 2,234,382.7077
Date	24 September 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	57,167
Price	EUR 20.4628
Total	EUR 1,169,796.8876
Date	23 September 2019
Name	Cord Dohrmann
Position	Member of Management
Type	Purchase of Shares by exercising stock options (Share Performance Plan)
No of items	26,900
Price	EUR 20.3379
Total	EUR 547,089.51
Date	20 September 2019
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	27,078
Price	EUR 20.0086
Total	EUR 541,792.8708
Date	20 September 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	14,050
Price	EUR 20.0086
Total	EUR 281,120.83
Date	03 September 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 19.00
Total	EUR 190,000.00
Date	19 August 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 18.866059
Total	EUR 188,660.59
Date	15 August 2019
Name	Cord Dohrmann
Position	Member of Management
Type	Purchase
No of items	1,000
Price	EUR 19.0375
Total	EUR 19,037.50
Date	12 July 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	280
Price	EUR 24.40
Total	EUR 6,832.00
Date	12 July 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	290
Price	EUR 24.40
Total	EUR 7,076.00
Date	04 July 2019
Name	Craig Johnstone
Position	Member of Management
Type	Exercise against Cash Settlement (Stock option programme)
No of items	7,126
Price	EUR 23.9312
Total	EUR 170,533.7312
Date	03 July 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	55,000
Price	EUR 24.50
Total	EUR 1,347,500.00
Date	03 July 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	84,630
Price	EUR 24.50
Total	EUR 2,073,435.00
Date	31 May 2019
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Stock option programme)
No of items	50,000
Price	EUR 19.4458
Total	EUR 972,290.00
Date	29 May 2019
Name	Craig Johnstone
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	7,000
Price	EUR 21.6392
Total	EUR 151,474.40
Date	12 Feb 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	30,000
Price	EUR 19.5429
Total	EUR 586,287.00
Date	12 Feb 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	70,000
Price	EUR 19.5429
Total	EUR 1,368,003.00
Date	11 Feb 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	30,000
Price	EUR 19.2454
Total	EUR 577,362.00
Date	11 Feb 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	70,000
Price	EUR 19.2454
Total	EUR 1,347,178.00
Date	22 Jan 2019
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	50,000
Price	EUR 19.3282
Total	EUR 966,410.00
Date	11 Jan 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	80,190
Price	EUR 19.0599
Total	EUR 1,528,413.38
Date	11 Jan 2019
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	69,810
Price	EUR 19.0599
Total	EUR 1,330,571.62
Date	29 Nov 2018
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Stock option programme)
No of items	29,220
Price	EUR 17.6169
Total	EUR 514,765.82
Date	16 November 2018
Name	Mario Polywka
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	216,666
Price	EUR 18.8146
Total	EUR 4,076,484.12
Date	02 October 2018
Name	Mario Polywka
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	75,000
Price	EUR 17.6166
Total	EUR 1,321,245.00
Date	15 September 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Share Performance Plan)
No of items	59,905
Price	EUR 17.7711
Total	EUR 1,064,577.75
Date	15 September 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	55,000
Price	EUR 17.7711
Total	EUR 977,410.50
Date	07 September 2017
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	48,883
Price	EUR 16.6007
Total	EUR 811,492.02
Date	04 September 2017
Name	Mario Polywka
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	43,261
Price	EUR 15.5612
Total	EUR 673,193.0732
Date	23 August 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Stock option programme)
No of items	132,000
Price	EUR 13.57
Total	EUR 1,791,240.00
Date	23 August 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Stock option programme)
No of items	118,000
Price	EUR 13.57
Total	EUR 1,601,260.00
Date	18 August 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Stock option programme)
No of items	20,654
Price	EUR 12.639
Total	EUR 261,045.906
Date	18 August 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Stock option programme)
No of items	11,940
Price	EUR 12.639
Total	EUR 150,909.66
Date	17 August 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	55,400
Price	EUR 14.5105
Total	EUR 803,881.70
Date	15 August 2017
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	28,000
Price	EUR 12.08
Total	EUR 338,240.00
Date	31 March 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Stock option programme)
No of items	31,000
Price	EUR 6.908
Total	EUR 214,148.00
Date	30 March 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Stock option programme)
No of items	37,000
Price	EUR 6.6904
Total	EUR 247,544.80
Date	30 March 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Stock option programme)
No of items	63,000
Price	EUR 6.6904
Total	EUR 421,495.20
Date	29 March 2017
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	20,000
Price	EUR 7.9329
Total	EUR 158,658.00
Date	29 March 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Exercise against Cash Settlement (Stock option programme)
No of items	63,000
Price	EUR 6.7029
Total	EUR 422,282.70
Date	29 March 2017
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase of shares by exercising stock options (Stock option programme)
No of items	37,000
Price	EUR 6.7029
Total	EUR 240,007.30
Date	17 February 2017
Name	Mario Polywka
Position	Member of Management
Type	Exercise against Cash Settlement (Share Performance Plan)
No of items	52,313
Price	EUR 6.274
Total	EUR 328,211.762
Date	15 February 2017
Name	Cord Dohrmann
Position	Member of Management
Type	Exercise against Cash Settlement (Stock option programme)
No of items	50,000
Price	EUR 5.0868
Total	EUR 254,340.00
Date	16 August 2016
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase (Stock option programme)
No of items	29,220
Price	EUR 2.65
Total	EUR 77,433.00
Date	29 March 2016
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	20,000
Price	EUR 3.072342
Total	EUR 61,446.84
Date	15 September 2014
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 3.057655
Total	EUR 30,576.55
Date	24 August 2012
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	20,000
Price	EUR 2.50
Total	EUR 50,000
Date	29 December 2011
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	12,000
Price	EUR 2.30
Total	EUR 27,600.00
Date	24 November 2011
Name	ROI Verwaltungsgesellschaft, Roland Oetker
Position	Member of Supervisory Board
Type	Purchase
No of items	10,000
Price	EUR 2.23297
Total	EUR 22,329.7
Date	07 September 2011
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 2.248
Total	EUR 22,480.00
Date	18 May 2011
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 2.668616
Total	EUR 26,686.16
Date	04 April 2011
Name	Werner Lanthaler
Position	Member of Management
Type	Loan
No of items	150,000
Price	EUR 0,00
Total	EUR 0,00
Date	11 November 2010
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 2.48
Total	EUR 24,800.00
Date	01 October 2010
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 2.30
Total	EUR 23,000.00
Date	30 September 2010
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 2.36782
Total	EUR 23,678.20
Date	12 May 2010
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	Eur 1.95
Total	EUR 19,500.00
Date	12 May 2010
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 1.96
Total	EUR 19,600.00
Date	29 March 2010
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 2.05
Total	EUR 20,500.00
Date	25 January 2010
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,530
Price	EUR 1.90
Total	EUR 20,007.00
Date	26 November 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 1.9927
Total	EUR 19,927.00
Date	22 September 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 1.4400
Total	EUR 14,400.00
Date	21 September 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 1.4500
Total	EUR 14,500.00
Date	02 September 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	10,000
Price	EUR 1.4900
Total	EUR 14,900.00
Date	01 September 2009
Name	Mario Polywka
Position	Member of Management
Type	Purchase
No of items	30,000
Price	GBP 1.345
Total	GBP 40,350.00
Date	27 August 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	4,000
Price	EUR 1.60
Total	EUR 6,400.00
Date	11 August 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	25,000
Price	EUR 1.4400
Total	EUR 36,000.00
Date	29 June 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	11,000
Price	EUR 0.9300
Total	EUR 10,230.00
Date	19 June 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	15,000
Price	EUR 0.7900
Total	EUR 11,850.00
Date	18 June 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	3,720
Price	EUR 0.7600
Total	EUR 2,827.20
Date	17 June 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	4,900
Price	EUR 0.7600
Total	EUR 3,724.00
Date	03 June 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	13,350
Price	EUR 0.7496629
Total	EUR 10,007.999715
Date	18 May 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	11,649
Price	EUR 0.65
Total	EUR 7,571.85
Date	15 May 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	65,351
Price	EUR 0.65
Total	EUR 42,478.15
Date	14 May 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	31,250
Price	EUR 0.6370585
Total	EUR 19,908.08
Date	13 May 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	12,329
Price	EUR 0.65
Total	EUR 8,013.85
Date	12 May 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	37,671
Price	EUR 0.65
Total	EUR 24,486.15
Date	22 April 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	15,900
Price	EUR 0.66
Total	EUR 10,494.00
Date	16 April 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	31,000
Price	EUR 0.6474193
Total	EUR 20,070.00
Date	27 March 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	40,000
Price	EUR 0.831375
Total	EUR 33,255.00
Date	06 March 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	25,000
Price	EUR 0.7169736
Total	EUR 17,924.34
Date	06 March 2009
Name	Werner Lanthaler
Position	Member of Management
Type	Purchase
No of items	3,000
Price	EUR 0.6900
Total	EUR 2,070.00

Expand table

Directors' Shareholdings

as of 30 June 2023

Outstanding Shares from vested SPA's

Granted unvested SPA's (total)

Management Board

Dr Werner Lanthaler

1,540,906

241,824

Dr Cord Dohrmann

195,079

115,201

Dr Matthias Evers

39,353

Dr Craig Johnstone

20,161

108,197

Laetitia Rouxel

51,655

42,488

Supervisory Board

Prof. Dr Iris Löw-Friedrich

Roland Sackers

Camilla Macapili Languille

Dr Mario Polywka

11,938

Dr Constanze Ulmer-Eilfort

Dr Elaine Sullivan

Management Board
Shares
Outstanding Shares from vested SPA's
Granted unvested SPA's (total)
Dr Werner Lanthaler
Shares	1,540,906
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	241,824
Dr Cord Dohrmann
Shares	195,079
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	115,201
Dr Matthias Evers
Shares	-
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	39,353
Dr Craig Johnstone
Shares	20,161
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	108,197
Laetitia Rouxel
Shares	51,655
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	42,488

Shares
Outstanding Shares from vested SPA's
Granted unvested SPA's (total)

Shares
Outstanding Shares from vested SPA's
Granted unvested SPA's (total)
Supervisory Board
Shares
Outstanding Shares from vested SPA's
Granted unvested SPA's (total)
Prof. Dr Iris Löw-Friedrich
Shares	-
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	-
Roland Sackers
Shares	-
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	-
Camilla Macapili Languille
Shares
Outstanding Shares from vested SPA's
Granted unvested SPA's (total)
Dr Mario Polywka
Shares	11,938
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	-
Dr Constanze Ulmer-Eilfort
Shares	-
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	-
Dr Elaine Sullivan
Shares	-
Outstanding Shares from vested SPA's	-
Granted unvested SPA's (total)	-

For a detailed description of the stock option plans and Share Performance Awards for the directors and employees of Evotec Group, please refer to the latest financial reports.

Share Performance Plan

To incentivise executives via variable long-term incentive compensation, the 2012, 2015 and 2017 Annual General Meetings approved the contingent capital necessary to support the so-called Share Performance Plans (SPP 2012, SPP 2015 and SPP 2017). SPP 2017 is replacing SPP 2012 and SPP 2015. However, this does not affect subscription rights issued before 14 June 2017.

The concrete design of the Share Performance Plans 2012, 2015 and 2017 lean on the concept of a share performance programme. They are characterised by the fact that participating executives are entitled to a variable remuneration in shares, when attaining a demanding target. In contrast to a common stock option programme, when attaining a target, shares are not issued in an amount that at least corresponds to the market rate of the company stock at the time of granting the subscription rights, but at the respectively lowest issue amount of currently € 1.00. The essential reason for this lies in the fact that in a Share Performance Programme, the value of the respective stock takes the place of cash compensation, so that stocks ideally should be issued without counter performance. A special economic advantage, compared to a common stock option programme, does not result for the participants as at the time the subscription rights are granted, and therefore at the outset, it is taken into consideration that the participants receive the total value of the shares (minus the respectively lowest issue amount of currently € 1.00), and not only, as in regular stock option plans, the difference between the market rate when granting subscription rights and the market rate at issue of the shares. The determination of an issue amount of currently € 1.00 is imperative from a corporate law perspective, as the issue of new shares under the respective pro-rata amount of the share capital is not permitted.

Under these plans, Share Performance Awards may be granted to a level that may result in in a total of up to 13,000,000 (4,000,000 for SPP 2012, 3,000,000 for SPP 2015 and 6,000,000 for SPP 2017) bearer shares of the Company being issued at maturity to members of the Management Board and other key employees. During the fourth quarter of 2016, a total of 793,903 SPAs (2015: 796,617 awards) were granted to the Management Board and key employees. These awards could result in a maximum of 1,587,806 bearer shares (2015: 1,593,234) being issued at maturity. This is because each Share Performance Award grants up to two subscription rights to Company shares, each of which in turn entitle the holder to the subscription of one Company share. Previous awards can be found the respective annual financial reports. The holder has to contribute € 1.00 per share at the date of issue. Share Performance Awards can only be exercised, if, when and to the extent that key performance indicators are achieved. Key performance indicators of SPP 2012 and 2015 are “Group Revenues”, “Operating Income Before Impairments”, “Net Cash Generated by Operating Activities” and “Share Price” upon which the Supervisory Board had to determine at least two per grant and define their weighting. SPP 2015 also includes the key performance indicator of “Total Shareholder Return”. Equally weighted key performance indicators of SPP 2017 are only “Share Price” and “Total Shareholder Return”.

Key parameters of the Company’s Share Performance Plan 2017 are depicted in the graphic below.

Show fullscreen

Detailed information on the Company’s current SPP 2017 as well as previous Share Performance Plans 2012 and 2015 can be found below.

Downloads

Share Performance Plan 2012PDF, 152.0 KB

Share Performance Plan 2015PDF, 231.6 KB

Share Performance Plan 2017PDF, 141.5 KB

Expiration of stock option schemes

SPP 2012, SPP 2015 and SPP 2017 were implemented to replace the stock option programme as the Company’s long-term incentive compensation scheme for executives. Stock options issued in existing stock option schemes I to VII remain valid.

Date of the Ordinary Annual General Meeting

Programme

07 June 1999

Programme I

26 June 2000

Programme II

18 June 2001

Programme III

07 June 2005

Programme IV

30 May 2007

Programme V

28 August 2008

Programme VI

16 June 2011

Programme VII

Date of the Ordinary Annual General Meeting	07 June 1999
Programme	Programme I
Date of the Ordinary Annual General Meeting	26 June 2000
Programme	Programme II
Date of the Ordinary Annual General Meeting	18 June 2001
Programme	Programme III
Date of the Ordinary Annual General Meeting	07 June 2005
Programme	Programme IV
Date of the Ordinary Annual General Meeting	30 May 2007
Programme	Programme V
Date of the Ordinary Annual General Meeting	28 August 2008
Programme	Programme VI
Date of the Ordinary Annual General Meeting	16 June 2011
Programme	Programme VII

Detailed information duration of the Company’s previous stock option programmes and exercising of options can be found below.

Downloads

Duration of Programmes and Exercising of OptionsPDF, 213.1 KB

Compliance and Code of Conduct

The Management Board ensures the observance of legal requirements and internal corporate guidelines, working to achieve compliance throughout the Group. Evotec’s corporate culture is committed to the highest standards of openness, integrity and accountability. Compliance is a key element of integrity, which means adherence to applicable laws and the Company’s internal policies. Evotec’s commitment to a compliance-oriented culture is reflected in the Company’s Code of Conduct, which stipulates fundamental ethical principles that apply to board members and other employees alike, such as integrity and professionalism.

The Code of Conduct mainly sets standards for:

Accounting and the permissible use of the Company’s funds and assets
Anti-money laundering principles
Compliance with insider trading laws and prevention of conflicts of interest
Compliance with antitrust legislation
Compliance with anti-corruption laws and associated internal guidelines
A work environment free of any form of discrimination and harassment
Occupational health & safety and environmental aspects
Animal welfare
Non-disclosure and protection of intellectual property and business secrets
Data protection and the use of personal data
Global trade
The duty to report upon the suspicion of an infringement of the Code of Conduct (whistle-blowing)

Evotec does not tolerate any violation of applicable laws or internal policies.

The Code of Conduct was revised in 2019, and a Supplier Code of Conduct (“SCoC”) was added in 2022. The Code of Conduct in Evotec's corporate languages as well as the English SCoC can be found below:

Code of Conduct

pdf

Code of Conduct (English)

PDF

657 kb

pdf

Code of Conduct (German)

PDF

698 kb

pdf

Code of Conduct (Italian)

PDF

285 kb

pdf

Code of Conduct (French)

PDF

709 kb

pdf

Supplier Code of Conduct (English)

PDF

344 kb

Further legal documents

pdf

Aptuit organisational model (English)

PDF

466 kb

pdf

Aptuit Ethical Rules (English)

PDF

175 kb

pdf

Aptuit organisational model (Italian)

PDF

564 kb

pdf

Aptuit Ethical Rules (Italian)

PDF

174 kb

pdf

Group Policy on insider information (November 2021)

PDF

229 kb

Reporting Compliance Concerns

The Evotec Group provides employees and external stakeholders with EVOwhistle as a channel to report compliance-related concerns such as suspected or observed misconduct, violations of the Evotec Code of Conduct or other legal violations. EVOwhistle is Evotec Group´s dedicated and secure website hosted outside the Evotec Group´s network. It aims to create a trusted system with protection for a Whistleblower and the person, which may be subject of an addressed concern. To access the platform, click the following link: EVOwhistle

TOP